Inloggen

Login
 
Wachtwoord vergeten?

Zealand Pharma (ZEAL)

Volgen
 
Klik hier om dit forumtopic te volgen en automatisch op de hoogte gehouden te worden bij nieuwe berichten.
156 Posts, Pagina: « 1 2 3 4 5 6 7 8 » | Laatste
Aantal posts per pagina:  20 50 100 | Omlaag ↓
Wil Helmus
0
Nog even geduld hebben:
The final Phase 3 trial that will complete our NDA application is in pediatric diabetes patients and is still ongoing. Recruitment for this study involving children has proved challenging and results are now expected in September 2019. Accounting for this delay in pediatric patient recruitment, submission of the new drug application (NDA) to the U.S. FDA is now expected early 2020.
Wil Helmus
0
Zealand Pharma A/S (ZEAL) PT Raised to $32 at Needham & CompanyAugust 15, 2019 3:59 PM 

Needham & Company analyst Alan Carr raised the price target on Zealand Pharma A/S (NASDAQ: ZEAL) to $32.00 (from $29.00) ...

Wil Helmus
0
Company announcement – No. 25 / 2019

Zealand Pharma delivers strong clinical results during the first half of 2019 and accelerates commercial build-up in the U.S.

www.globenewswire.com/news-release/20...
Wil Helmus
0
ZEALAND PHARMA/S (NASDAQ:ZEAL) had its price objective boosted by Morgan Stanley from $29.00 to $30.00 in a research note released on Monday, BenzingaRatingsTable reports. Morgan Stanley currently has an overweight rating on the stock.
Wil Helmus
0
Zealand Pharma relocates headquarters to accommodate growth

Press Release – No. 18 / 2019


Copenhagen, August 27, 2019 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces the relocation into new corporate headquarters located at Sydmarken 11 in Søborg, approximately 12 kilometers from its current facilities.

Relocation is planned to begin in September 2019, with the phased move of laboratories completing by the end of the year. The move will accommodate Zealand’s continued workforce growth, which has been steadily increasing to support the number of clinical development programs as well as the longer-term strategic initiative for introducing commercial support. Operations will be able to expand within 7,100 square meters of newly renovated offices and laboratories, and will provide a more open and collaborative working environment.

“This is an exciting time for Zealand Pharma. Extensive thought and effort went into making the decision to relocate from our offices in Glostrup that has been our home for 20 years. However, with our commercial ambitions, we have realized the need to provide head room for growth in addition to modern facilities that will strengthen productivity, talent attraction, and employee satisfaction,” said Emmanuel Dulac, President and Chief Executive Officer at Zealand Pharma. “Moving to the new headquarters is a reflection of the success built during the past two decades, and is a milestone in our journey to become a fully integrated biotech company.”

The new headquarters in Søborg will consist of two office and laboratory buildings with an attached meeting center. There will be abundant meeting rooms interspersed throughout open office space to foster innovation, collaboration, and productivity. The decor will reflect Scandinavian design with numerous modern technology upgrades.

rbot
0
Ik heb nog niks inhoudelijks kunnen vinden waarom de koers onderuit gaat. Marktsentiment of is er toch wat meer aan de hand?

Iemand een idee wanneer we de fase 3 mogen verwachten. Ergens h2 meen ik mij te herinneren?
rbot
0
Wil Helmus
0
quote:

rbot schreef op 27 aug 2019 om 18:47:


Ik heb nog niks inhoudelijks kunnen vinden waarom de koers onderuit gaat. Marktsentiment of is er toch wat meer aan de hand?

Iemand een idee wanneer we de fase 3 mogen verwachten. Ergens h2 meen ik mij te herinneren?


Ik denk dat Zealand het tactisch niet heel handig heeft gespeeld door een exacte maand te noemen voor de fase 3 resultaten. Tot september is er verder weinig nieuws te verwachten. Ik verwacht dat er vanaf maandag weer wat fantasie in de koers zal komen. Zal wel fijn zijn als we tegen die tijd niet onder de 100DKK staan....
Wil Helmus
0
Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes


Zealand Pharma company announcement – No. 29 / 2019


•The dual acting GLP-1/glucagon peptide BI 456906 is a part of Boehringer Ingelheim’s pipeline portfolio in obesity and diabetes

•The Phase 2 trial for BI 456906 is expected to be initiated in late 2019 and will trigger a EUR 20 million milestone payment to Zealand Pharma out of total outstanding potential milestone payments of EUR 365 million and high single to low double digit royalties on future sales



INGELHEIM, Germany and COPENHAGEN, Denmark, September 3, 2019 – Boehringer Ingelheim and Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL), have announced that Boehringer Ingelheim plans to initiate Phase 2 development of the GLP-1/glucagon dual agonist BI 456906, which was in-licensed from Zealand. Boehringer Ingelheim and Zealand have a longstanding partnership, bringing together Zealand’s expertise in the discovery of innovative peptide-based medicines with Boehringer Ingelheim’s expertise in the research and development of novel medicines for cardiometabolic diseases.

The compound derived from the natural gut hormone oxyntomodulin activates both the GLP-1 and glucagon receptors that are critical to controlling metabolic functions. The dual agonist BI 456906 has potential as a new, once-weekly treatment that may offer therapeutically relevant benefits compared to currently available treatments.1 It is part of Boehringer Ingelheim’s growing research and development stage portfolio in the obesity and diabetes disease areas.

The decision to advance BI 456906 to Phase 2 clinical testing is based on the safety and tolerability and the favorable weight loss potential in individuals with a BMI up to 40 kg/m2. The Phase 2 trial will be a dose-finding, placebo and active comparator clinical proof of concept trial in patients with obesity and type 2 diabetes.

“We believe that BI 456906 has great therapeutic potential, and we are thrilled to see it advance into Phase 2 development,” said Emmanuel Dulac, President and Chief Executive Officer at Zealand Pharma. “Our strong partnership with Boehringer Ingelheim unites expertise and capabilities to achieve a shared vision of helping millions of people better manage and overcome obesity and type 2 diabetes.”

“We are excited to see this candidate from our dedicated and productive long-term collaboration with Zealand Pharma proceed to the next stage of clinical studies,” explained Clive R. Wood, Ph.D., Senior Corporate Vice President, Discovery Research at Boehringer Ingelheim. “This brings us an important step further to bringing BI 456906 to the many patients that are in need of new treatment options.”

Zealand has licensed two product candidates to Boehringer Ingelheim, both with potential for once-weekly administration. Under the terms of the two agreements, Boehringer Ingelheim funds all research, development and commercialization activities. For the GLP-1/glucagon dual agonist, Zealand is entitled to receive up to EUR 365 million in outstanding milestone payments and will receive a milestone payment of EUR 20 million related to initiation of Phase 2. The agreement also carries high-single digit to low-double digit percentage royalties on global sales. The other collaboration compound is a long-acting amylin analog for which Zealand is entitled to receive up to EUR 283 million in outstanding milestone payments, and mid-single digit to low-double digit percentage royalties on global sales.

Excessive weight and obesity are amongst the leading risk factors for heart disease, ischemic stroke, liver diseases and type 2 diabetes as well as for a number of cancers. There are insufficient therapeutic options available, resulting in a high unmet medical need for safe and effective treatments that achieve significant weight loss. Boehringer Ingelheim’s track record of excellence in research and development in cardiometabolic diseases is evidence of its innovation which has resulted in important breakthroughs in recent years, especially in thromboembolic diseases and type 2 diabetes.

###

About Boehringer Ingelheim
Improving the health of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of around 17.5 billion euros. R&D expenditure of almost 3.2 billion euros, corresponded to 18.1 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: annualreport.boehringer-ingelheim.com.

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealand’s portfolio also includes two clinical license collaborations with Boehringer Ingelheim and pre-clinical license collaboration with Alexion Pharmaceuticals.
Wil Helmus
0
Van Herk heeft er vertrouwen in:

Zealand Pharma announces private placement and directed issue of new shares with expected gross proceeds of DKK 559.6 million

Company announcement – No. 30 / 2019

•A total of 3,975,000 new shares (the "New Shares") have been subscribed for with expected gross proceeds of approx. DKK 559.6 million
•The private placement and directed share issue to existing shareholder Van Herk Investments B.V follows recent positive developments in Zealand Pharma’s product pipeline
•The additional funding will be used to continue supporting Zealand Pharma’s peptide platform, accelerate ongoing development of late stage assets, and prepare for the launch of the company’s first fully-owned asset



Copenhagen, September 5, 2019 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces a private placement and directed share issue to Van Herk Investments B.V of 3,975,000 New Shares, each of a nominal value of DKK 1, at a subscription price of DKK 140.79 per New Share (the "Placement"). Zealand expects to receive gross proceeds from the Placement of approximately DKK 559.6 million.

Van Herk Investments is a long-term investor in biotech and had been the largest shareholder in Ablynx, which was sold to Sanofi for $4.8 billion in 2018. More recently, Van Herk Investments increased their stake in a $8 billion+ market cap drug developer Galapagos to 10%. Van Herk Investments has been among the top three shareholders of Zealand Pharma since early 2018.

The board of directors of Zealand has on 5 September 2019 in accordance with article 7.1 of Zealand's articles of association, exercised an authorization granted by Zealand's general meeting to increase Zealand's share capital and issue the New Shares.

The New Shares will be issued without pre-emption rights for Zealand's current shareholders and the New Shares will upon issuance rank pari passu with Zealand's existing shares and carry the same dividend and other rights. Each New Share carries one vote at Zealand's general meetings. Zealand only has one class of shares.

Payment of the subscription price is expected to take place no later than 10 September 2019 after which the capital increase will be registered with the Danish Business Authority.

Morgan Stanley & Co. LLC has acted as placing agent for the Placement.

Zealand intends to use the gross proceeds from the subscription together with its existing cash resources for the following purposes:
•Contribute to supporting discovery, research and development of the company’s peptide platform,
•Support ongoing development of late stage assets, and
•Prepare for the launch of the company’s first fully-owned asset.

The New Shares will be issued and registered with VP Securities and admitted to trading on Nasdaq Copenhagen under the ISIN code of Zealand's existing shares (ISIN code DK0060257814) once the subscription price has been paid and the new shares have been registered with the Danish Business Authority. Admission to trading of the New Shares is expected to take place on 11 September 2019.

Before the Placement, Zealand's share capital amounted to DKK 31,831,290. After completion of the Placement and issue of the New Shares, Zealand's share capital will amount to normally DKK 35,806,290, corresponding to 35,806,290 shares of DKK 1, nominal value, each.

Expected timetable for the capital increase:

10 September 2019 Registration of the New Shares with the Danish Business Authority as well as issue and registration of the new shares with VP Securities.
11 September 2019 Admittance to trading on Nasdaq Copenhagen of the New Shares.

The New Shares will be listed on Nasdaq Copenhagen in reliance on the exemption in article 1(5)a of the Prospectus Regulation and not on the basis of a prospectus.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

The securities offered in the Placement will not be, and have not been, registered under the Securities Act of 1933, as amended (the “Act”), and may not be offered or sold in the United States absent a registration statement or an applicable exemption from the registration requirements under the Act.




Important information

No announcements or information regarding the Placement may be disseminated to the public in jurisdictions where a prior registration or approval is required for such purpose. No steps have been taken, or will be taken, for the offering of shares or ADSs in any jurisdiction where such steps would be required. The issue or sale of ADSs, and the subscription for or purchase of ADSs, are subject to special legal or statutory restrictions in certain jurisdictions. Zealand is not liable if these restrictions are not complied with by any other person.




Forward-Looking Statements

This announcement may contain forward-looking statements, including “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, that are based on the beliefs and assumptions and on information currently available to management of Zealand, including with respect to the closing of the Placement described herein. All statements other than statements of historical fact contained in this announcement are forward-looking statements, including statements regarding the anticipated final terms of the Investment. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Zealand's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Zealand's Annual Report on Form 20-F for the year ended December 31, 2018 filed with the SEC on March 15, 2019 and subsequent reports that Zealand files with the SEC. Forward-looking statements represent Zealand's beliefs and assumptions only as of the date of this announcement. Although Zealand believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, Zealand assumes no obligation to publicly update any forward-looking statements for any reason after the date of this announcement to conform any of the forward-looking statements to actual results or to changes in its expectations.


Wil Helmus
0
Zealand Pharma major shareholder announcement: Van Herk Investments


Company announcement – No. 31 / 2019

Zealand Pharma major shareholder announcement: Van Herk Investments

Copenhagen, September 5, 2019 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces that it today has received the following major shareholder notification:

As from 5 September 2019, Van Herk Investments B.V. (Dutch registration no. 59055057) holds nominally DKK 6,714,730 shares (each share carrying one vote) in Zealand Pharma A/S, corresponding to 18.75% of the total share capital and total voting rights Zealand Pharma A/S.

Van Herk Investments B.V. is 100% owned by, Van Herk Private Equity Investments B.V. (Dutch registration no. 58894543, which is ultimately owned and controlled by Mr. Adrianus van Herk.

Van Herk Management Services B.V. (Dutch registration no. 24377325) controls and exercises the voting rights on behalf of Van Herk Investments B.V., and accordingly, Van Herk Management Services B.V controls and exercises the voting rights on nominally DKK 6,714,730 shares (each share carrying one vote), corresponding to 18.75% of the total share capital and total voting rights in Zealand Pharma A/S.

Van Herk Management Services B.V., is controlled by OGBB A. van Herk B.V. (Dutch registration no. 24160906), which is controlled by A. van Herk Holding B.V. (Dutch registration no. 24160780), which is ultimately controlled by Mr. Adrianus van Herk.

Notification to the Danish FSA has been made as well.
poolbeer
0
DeZwarteRidder
0
quote:

poolbeer schreef op 6 sep 2019 om 12:54:


Bij welke broker kan je Zealand kopen? Bij Rabobank niet mogelijk.
bvd.

Bij de ABN kan het wel.
156 Posts, Pagina: « 1 2 3 4 5 6 7 8 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

Markt vandaag

Europese beurzen sluiten grotendeels in de min

20 jan De Europese aandelenbeurzen zijn maandag overwegend lager gesloten. Beleggers deden het rustig aan na de re...

    Indices

    AEX 614,23 -0,22%
    EUR/USD 1,1097 0,00%
    Germany30^ 13.565,50 +0,12%
    Gold spot 1.567,09 +0,27%
    LDN100-24h 7.632,33 -0,31%
    NY-Nasdaq Composite 9.388,94 +0,34%
    US30# 29.259,16 -0,31%

    Stijgers

    Alfen ...
    +3,25%
    Fagron
    +3,19%
    Arcadis
    +3,14%
    Sif Ho...
    +2,78%
    Galapagos
    +2,76%

    Dalers

    Air Fr...
    -4,63%
    Kiadis...
    -2,14%
    Ajax
    -1,95%
    ABN AM...
    -1,83%
    Vopak
    -1,81%